Skip to main content

Advertisement

Table 3 Correlation between D-CEUS parameters and PFS and DMFS

From: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Parameter changes < 30% ≥ 30% P value
3-year estimate (%, 95% CI)
PFS (day 8)
 Peak intensity 90.9 (73.7–100) 44.4 (11.9–76.9) 0.021
 Area under the curve 90.0 (71.4–100) 50.0 (31.0–81.0) 0.048
 Slope of wash-in (coefficient) 90.9 (73.7–100) 44.4 (11.9–76.9) 0.021
 Wash-in perfusion index 90.9 (73.7–100) 44.4 (11.9–76.9) 0.021
DMFS (day 8)
 Peak intensity 90.9 (73.7–100) 55.6 (23.1–88.1) 0.065
 Area under the curve 90.0 (71.4–100) 60.0 (23.1–88.2) 0.119
 Slope of wash-in (coefficient) 90.9 (73.7–100) 55.6 (23.1–88.1) 0.065
 Wash-in perfusion index 90.9 (73.7–100) 55.6 (23.1–88.1) 0.065
PFS (day 15)
 Peak intensity 94.1 (82.9–100) 0.0 < 0.001
 Area under the curve 92.3 (77.8–100) 42.9 (6.2–79.6) 0.038
 Slope of wash-in (coefficient) 86.7 (69.5–100) 20.0 (0–55.1) 0.002
 Wash-in perfusion index 80.0 (59.8–100) 40.0 (0–82.9) 0.072
DMFS (day 15)
 Peak intensity 88.2 (72.9–100) 0.0 < 0.001
 Area under the curve 84.6 (65.0–100) 57.1 (20.4–93.8) 0.16
 Slope of wash-in (coefficient) 93.3 (80.8–100) 20.0 (0–55.1) < 0.001
 Wash-in perfusion index 86.7 (69.5–100) 21.9 (0–82.9) 0.024
  1. D-CEUS dynamic contrast enhanced ultrasound, PFS progression-free survival, DMFS Distant metastasis-free survival, CI confidence interval